New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of ...

Hereditary Angioedema Companies are Ionis Pharmaceuticals, Astria Therapeutics, KalVista Pharmaceuticals, Intellia Therapeutics, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals ...

Dr. Marc A. Riedl, Professor of Medicine and Clinical Director of the U.S. HAEA Angioedema Center at the University of California, San Diego, will present safety and efficacy data from the Phase ...

The FDA has accepted the New Drug Application for berotralstat as prophylactic therapy for pediatric patients aged 2 to 11 years with hereditary angioedema.

Pharvaris, a biopharmaceutical company based in Zug, Switzerland, announced the acceptance of multiple abstracts for presentation at three significant upcoming congresses focusing on angioedema ...

Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.

Intellia Therapeutics shares fell 25% amid safety concerns in Phase 3 trials. Check out if today's selloff in NTLA stock is a ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will present new sebetralstat data at two upcoming congresses taking place concurrently from May 29-June 1, 2025: the 14th ...

The Business Research Company's Hereditary Angioedema Global Market Report 2025 - Market Size, Trends, And Global Forecast 2025-2034 The Business Research Company's Latest Report Explores Market ...

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment ...

In the assessment of 12-month price targets, analysts unveil insights for Intellia Therapeutics, presenting an average target ...